News

Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel

BOULDER, CO / ACCESSWIRE / November 11, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microcyn technology-based hydrogel, including improved biocompatibility and extended shelf life. Per this new clearance, Sonoma's Microdacyn® Hydrogel can be used under the supervision of a healthcare professional for management of wounds associated with dermal irritation, sores, injuries and ulcers of dermal tissue, for use on first and second degree burns, and diabetic ulcers, and for the management of mechanically or surgically debrided wounds.

11/11/2024

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2025 Financial Results

Revenue increased 31% for the quarter compared to same period prior year Positive cash flows from operations of $0.35 million for the quarter Net loss improved 59% for the quarter compared to same period prior year Net loss per share improved 90% for the quarter compared to same period prior year BOULDER, CO / ACCESSWIRE / November 7, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced financial results for its second fiscal quarter ended September 30, 2024. "Our results this quarter reflect the diligent efforts by Sonoma's team to grow our business and drive toward profitability," said Amy Trombly, CEO of Sonoma.

11/07/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Sonoma Pharmaceuticals, Inc. (SNOA) a buy, sell, or hold?

Sonoma Pharmaceuticals, Inc. (SNOA) can sell. Click on Rating Page for detail.

What is Sonoma Pharmaceuticals, Inc.'s stock price?

The price of Sonoma Pharmaceuticals, Inc. (SNOA) is 2.86 and it was updated on 2024-11-20 13:00:33.

Is Sonoma Pharmaceuticals, Inc. (SNOA) overvalued or undervalued?

Currently Sonoma Pharmaceuticals, Inc. (SNOA) is in undervalued.

News

From:

To:

News
Sonoma Pharmaceuticals to Exhibit at MEDICA 2024 in Düsseldorf BOULDER, CO / ACCESSWIRE / October 31, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it will be exhibiting at MEDICA 2024 in Düsseldorf, Germany November 11-14, 2024. MEDICA is considered the largest and most prestigious medical trade fair in the world, expected to attract over 120,000 visitors from more than 70 countries and over 5,300 exhibitors, showcasing the latest innovations in medical technology, diagnostics, and healthcare IT. Thu, Oct. 31, 2024
Sonoma Pharmaceuticals Announces Expanded Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in Canada BOULDER, CO / ACCESSWIRE / October 22, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it has entered into an amendment to its distribution agreement with a leading global healthcare distributor for the marketing and distribution of its wound care products in Canada. As previously announced, on August 19, 2024, Sonoma entered into a distribution agreement with a global healthcare distributor for the marketing and distribution of its wound care products in the United States, to be sold through hospital systems and other healthcare channels. Tue, Oct. 22, 2024
Sonoma Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule BOULDER, CO / ACCESSWIRE / September 19, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it received a formal determination letter from Nasdaq notifying Sonoma that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market and the matter is now closed. As previously reported, On September 22, 2023, Sonoma received a letter from Nasdaq indicating that it did not comply with the $1.00 minimum closing bid price requirement for its common stock for continued listing on the Nasdaq Capital Market. Thu, Sep. 19, 2024
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution BOULDER, CO / ACCESSWIRE / September 17, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microcyn technology-based solution, including specific over-the-counter indications for the face, eyelid and eyelashes. Per this new clearance, Sonoma's Microcyn wound care solution can be used for OTC management of minor skin abrasions, lacerations and irritations, and intact skin on the face, eyelid and eyelashes. Tue, Sep. 17, 2024
Sonoma Pharmaceuticals and EMC Pharma Announce Collaboration to Co-market an Expanded Eye Care Product Line BOULDER, CO / ACCESSWIRE / September 11, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, in partnership with EMC Pharma, LLC, today announced they have entered into a co-marketing agreement to launch and sell an expanded prescription and OTC eye care product line. The new eye care line will also feature refreshed design and improved packaging for Ocucyn® Eyelid & Eyelash Cleanser. Wed, Sep. 11, 2024

SEC Filings

SEC Filings
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/07/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 10/22/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/20/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 09/20/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/28/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/23/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 08/23/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/21/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - DEFA14A SEC Filings 08/15/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/08/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - DEFA14A SEC Filings 07/24/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/01/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/27/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 06/27/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - PRE 14A SEC Filings 06/21/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 06/21/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - S-8 SEC Filings 06/17/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 06/17/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 04/09/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 04/02/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 03/22/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 03/08/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 03/08/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/08/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 01/10/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 01/09/2024
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 12/29/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/29/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 12/18/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 12/15/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 11/22/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 11/21/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/13/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - S-3 SEC Filings 11/03/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B4 SEC Filings 10/30/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 10/27/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 10/13/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K/A - Current report SEC Filings 10/11/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 10/11/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/28/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1 SEC Filings 09/19/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - DEFA14A SEC Filings 09/15/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/10/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/27/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 07/21/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 07/14/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 07/03/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 06/21/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 05/10/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 04/13/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 04/13/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/24/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 02/24/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/14/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 01/31/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 01/06/2023
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 12/30/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/30/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 12/23/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 12/23/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/14/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 10/12/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 10/07/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/16/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/11/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/22/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 07/22/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 07/13/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - NT 10-K - Current report SEC Filings 06/29/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/11/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 01/20/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 01/14/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 01/14/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - S-8 SEC Filings 01/13/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 01/06/2022
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/15/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/09/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/21/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/03/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 09/03/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - DEFA14A SEC Filings 08/30/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - DEFA14A SEC Filings 08/23/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - DEFA14A SEC Filings 08/16/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/16/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/02/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 07/30/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 07/30/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/29/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 07/20/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 07/14/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 07/09/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 07/06/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - NT 10-K - Current report SEC Filings 06/29/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 03/31/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 03/04/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/16/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 01/13/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 01/11/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 01/08/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 01/08/2021
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 12/23/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 12/23/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 12/22/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 12/18/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 12/17/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - S-3/A SEC Filings 12/15/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 12/15/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 12/10/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 12/07/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - S-3 SEC Filings 11/24/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/20/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/17/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q/A - Quarterly Report SEC Filings 11/17/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - NT 10-Q - Quarterly Report SEC Filings 11/16/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/18/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/11/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 09/11/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/14/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/06/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/29/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 07/10/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - NT 10-K - Current report SEC Filings 06/29/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/29/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/04/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 05/26/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 05/04/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 04/24/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 04/23/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 04/20/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/27/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/14/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 25-NSE SEC Filings 01/22/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 01/03/2020
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 12/31/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - S-8 SEC Filings 12/26/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/29/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 11/27/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 11/26/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/14/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/06/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - DEFA14A SEC Filings 10/18/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 10/17/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 10/15/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 10/15/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - DEFA14A SEC Filings 10/09/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - DEFA14A SEC Filings 10/03/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 10/01/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - DEFA14A SEC Filings 09/18/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/13/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/29/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 07/01/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/19/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/12/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - DEFA14A SEC Filings 05/31/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 05/31/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 05/22/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 04/22/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - PRE 14A SEC Filings 04/12/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13G/A SEC Filings 02/14/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/14/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 01/15/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 01/11/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 01/08/2019
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 12/21/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - S-8 SEC Filings 12/19/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 12/14/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/28/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/21/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13D/A SEC Filings 11/20/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 11/20/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 11/19/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 11/16/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 11/16/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 11/16/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/08/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/08/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 11/07/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13D SEC Filings 11/05/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 10/23/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - CT ORDER SEC Filings 10/22/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1 SEC Filings 10/12/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 10/04/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 09/21/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/19/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/13/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/08/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/08/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/27/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 07/24/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - PRE 14A SEC Filings 07/17/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 06/26/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/13/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/05/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 06/01/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/14/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/13/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13G SEC Filings 03/09/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/08/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 03/06/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 03/05/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 03/02/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/02/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/14/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13G SEC Filings 02/13/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/07/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 01/03/2018
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 12/08/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 12/08/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/04/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/01/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 11/30/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 11/29/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 11/28/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 11/28/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 11/27/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 11/24/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 11/21/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - S-3/A SEC Filings 11/17/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 11/16/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/14/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - S-3 SEC Filings 11/09/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/09/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/01/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/11/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - CT ORDER SEC Filings 09/01/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 08/30/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 08/14/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 08/11/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 08/10/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/08/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/08/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/27/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 06/30/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - S-8 SEC Filings 06/29/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 06/28/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/05/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 06/01/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 04/07/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 04/07/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 04/05/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/13/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/09/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/08/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/07/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/02/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/17/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - NT 10-Q - Quarterly Report SEC Filings 02/14/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/09/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 01/23/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 01/20/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 01/10/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - CT ORDER SEC Filings 01/05/2017
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/12/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/08/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 12/07/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/02/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 12/01/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 11/30/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - S-8 SEC Filings 11/22/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 11/18/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - NT 10-Q - Quarterly Report SEC Filings 11/15/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/15/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/10/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 10/31/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 10/21/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-A12B SEC Filings 10/21/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K/A - Current report SEC Filings 09/19/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/09/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 09/09/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 08/30/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 08/16/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/09/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/29/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 07/29/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 07/28/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/28/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 06/21/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/16/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - CT ORDER SEC Filings 06/06/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 06/01/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 03/23/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 03/18/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 03/18/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B2 SEC Filings 03/17/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - CT ORDER SEC Filings 03/14/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/02/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 02/29/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/16/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13G/A SEC Filings 02/05/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/04/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13G/A SEC Filings 01/05/2016
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 12/16/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/02/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/10/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/05/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 10/27/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K/A - Current report SEC Filings 10/22/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 10/16/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 10/15/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - DEFA14A SEC Filings 09/24/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/15/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - DEFA14A SEC Filings 09/14/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 09/02/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 09/02/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - DEFA14A SEC Filings 08/27/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 08/25/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 08/10/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 08/10/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/07/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 07/30/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - POS AM SEC Filings 07/29/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/28/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - PRE 14A SEC Filings 07/17/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - POS AM SEC Filings 07/09/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 07/02/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13D/A SEC Filings 06/24/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - S-8 SEC Filings 06/23/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 06/23/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 06/16/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/11/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 06/08/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - CT ORDER SEC Filings 06/02/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 06/02/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - PRE 14A SEC Filings 05/27/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/24/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13D SEC Filings 03/23/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 03/16/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 03/12/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/03/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 03/02/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/12/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13G SEC Filings 01/30/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 01/26/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B2 SEC Filings 01/22/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 01/21/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 01/20/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 01/16/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - CERTNAS SEC Filings 01/16/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-A12B SEC Filings 01/16/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 01/13/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 01/12/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13G/A SEC Filings 01/07/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 01/07/2015
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 12/08/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/02/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1 SEC Filings 11/21/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 11/17/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/13/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/13/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 11/07/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - PRE 14A SEC Filings 10/27/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 10/01/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/12/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 08/12/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/12/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/07/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/01/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/29/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 07/22/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 07/22/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - S-3/A SEC Filings 07/17/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 07/16/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 06/30/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/12/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - S-3/A SEC Filings 05/15/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - S-8 SEC Filings 04/28/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - S-3 SEC Filings 04/28/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13G SEC Filings 04/10/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 04/03/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 04/02/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 04/02/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 04/01/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 04/01/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 03/31/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - CT ORDER SEC Filings 03/24/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/06/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 03/06/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - S-8 SEC Filings 03/04/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/26/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 02/25/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/14/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/13/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/06/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13G/A SEC Filings 01/07/2014
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/20/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 12/18/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 12/06/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 12/06/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/27/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/19/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/19/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - NT 10-Q - Quarterly Report SEC Filings 11/14/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 10/02/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 10/02/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K/A - Current report SEC Filings 09/24/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/24/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 09/20/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/17/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 09/10/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 08/19/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/14/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/08/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/05/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/29/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 06/27/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 06/25/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/13/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/07/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 05/30/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 05/29/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13G/A SEC Filings 04/23/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 03/22/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 03/22/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 03/07/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B2 SEC Filings 03/07/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 03/06/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13G SEC Filings 02/15/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/13/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/13/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 02/05/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 02/05/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/04/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13G/A SEC Filings 01/29/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - PRE 14A SEC Filings 01/25/2013
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 12/21/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/11/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/10/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/07/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 11/09/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/08/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/05/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/01/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - CT ORDER SEC Filings 10/24/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - CT ORDER SEC Filings 10/18/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 10/02/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/14/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q/A - Quarterly Report SEC Filings 08/31/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 08/27/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/15/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/03/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/02/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 07/30/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/27/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/27/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - S-8 SEC Filings 06/21/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/21/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 06/21/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/07/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 05/25/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 04/25/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13G SEC Filings 04/24/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 04/24/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/09/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 03/07/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/10/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/10/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 02/08/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/02/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 01/13/2012
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 12/28/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 12/27/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 12/05/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 12/05/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 12/01/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - S-3/A SEC Filings 11/29/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 11/29/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - CT ORDER SEC Filings 11/23/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 11/08/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/03/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/03/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 11/01/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - S-3 SEC Filings 10/21/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 10/04/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 09/23/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/16/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q/A - Quarterly Report SEC Filings 08/09/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/04/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/04/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/29/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 07/06/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 07/01/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/28/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 06/17/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 06/03/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/02/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 05/20/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 05/04/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - CT ORDER SEC Filings 05/04/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 05/02/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q/A - Quarterly Report SEC Filings 04/29/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - CT ORDER SEC Filings 04/01/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 04/01/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 03/17/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 03/07/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - CT ORDER SEC Filings 02/28/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - S-3/A SEC Filings 02/18/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 02/18/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/18/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/04/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/03/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 01/21/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 01/13/2011
Sonoma Pharmaceuticals, Inc. (SNOA) - S-8 SEC Filings 12/23/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - S-3 SEC Filings 12/23/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/22/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 12/17/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 11/08/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/04/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/04/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 10/29/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 09/30/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/17/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 09/03/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 08/09/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/05/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/05/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/29/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 06/10/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 06/09/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 06/08/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/03/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 05/06/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 04/02/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 03/11/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/11/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 02/11/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/11/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/04/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 02/02/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13G/A SEC Filings 01/08/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 01/07/2010
Sonoma Pharmaceuticals, Inc. (SNOA) - S-8 SEC Filings 12/23/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/09/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 12/08/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 12/08/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 11/18/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 11/12/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 11/10/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/10/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/05/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 09/10/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 09/08/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 09/04/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - POS AM SEC Filings 09/03/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 09/03/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 09/02/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 09/02/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 08/27/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 08/27/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 08/24/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 08/18/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 08/13/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 08/13/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 08/12/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - POS AM SEC Filings 08/07/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 08/07/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/07/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/06/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - AW SEC Filings 08/04/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 07/31/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/29/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1MEF SEC Filings 07/28/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B2 SEC Filings 07/28/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 07/27/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - POS AM SEC Filings 07/24/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 07/24/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 07/23/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 07/22/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 07/21/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 07/21/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 07/20/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 07/16/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - POS AM SEC Filings 07/15/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 07/09/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 07/09/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13D SEC Filings 07/08/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 07/01/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 06/19/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 06/18/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 06/17/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/11/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 06/11/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/04/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 06/03/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 06/03/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 05/22/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 05/22/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13G SEC Filings 05/15/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 04/27/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1 SEC Filings 04/10/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 03/30/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 03/27/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 03/24/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - REGDEX SEC Filings 03/12/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/12/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1 SEC Filings 03/09/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/09/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/06/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/05/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/27/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/13/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/12/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 02/09/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/09/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - REGDEX SEC Filings 02/04/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 01/29/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 01/09/2009
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 12/17/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/11/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/26/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/13/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/06/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 10/01/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 10/01/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/10/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 09/10/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 09/04/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 08/06/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/06/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/05/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - ARS SEC Filings 07/24/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 07/21/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - PRE 14A SEC Filings 07/03/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 06/16/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 06/13/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/11/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - SC 13G SEC Filings 05/16/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 04/30/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 04/30/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - FWP SEC Filings 03/28/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 03/28/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B5 SEC Filings 03/28/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 03/28/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 4/A SEC Filings 03/13/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/11/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 03/03/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 02/27/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/27/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 02/27/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - S-3 SEC Filings 02/13/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 02/08/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/08/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/07/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 01/28/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 01/18/2008
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 12/07/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 11/19/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 11/16/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 11/16/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 11/13/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 11/13/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 09/25/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 09/24/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 09/21/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 09/13/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B3 SEC Filings 09/13/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1 SEC Filings 08/30/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - ARS SEC Filings 08/29/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - REGDEX SEC Filings 08/23/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - DEF 14A SEC Filings 08/17/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K/A - Current report SEC Filings 08/17/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 08/15/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 08/14/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/13/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 08/09/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K/A - Current report SEC Filings 07/27/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 06/29/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 06/27/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-K - Current report SEC Filings 06/20/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 06/19/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 06/12/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 05/02/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 04/30/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 04/27/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 04/25/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 03/30/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 03/08/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - S-8 SEC Filings 03/01/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-K - Current report SEC Filings 02/23/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q - Quarterly Report SEC Filings 02/21/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 01/30/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - REGDEX/A SEC Filings 01/29/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 424B4 SEC Filings 01/26/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 4 SEC Filings 01/26/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - EFFECT SEC Filings 01/25/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - 3 SEC Filings 01/24/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 01/22/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - REGDEX SEC Filings 01/18/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - FWP SEC Filings 01/10/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - FWP SEC Filings 01/09/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 01/08/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 01/03/2007
Sonoma Pharmaceuticals, Inc. (SNOA) - FWP SEC Filings 12/21/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 12/21/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 12/20/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 12/20/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 12/18/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - CERTNAS SEC Filings 12/18/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - CORRESP SEC Filings 12/15/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - 8-A12B SEC Filings 12/15/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 12/14/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 12/01/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 11/27/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 11/13/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 10/12/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - REGDEX/A SEC Filings 10/10/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1/A SEC Filings 09/18/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - REGDEX SEC Filings 09/07/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - UPLOAD SEC Filings 07/28/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - REGDEX SEC Filings 07/21/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - REGDEX/A SEC Filings 07/19/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - REGDEX SEC Filings 07/19/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - S-1 SEC Filings 07/03/2006
Sonoma Pharmaceuticals, Inc. (SNOA) - REGDEX SEC Filings 07/12/2005
Sonoma Pharmaceuticals, Inc. (SNOA) - REGDEX/A SEC Filings 06/14/2005
Sonoma Pharmaceuticals, Inc. (SNOA) - REGDEX SEC Filings 05/06/2004
Sonoma Pharmaceuticals, Inc. (SNOA) - REGDEX SEC Filings 08/11/2003
Sonoma Pharmaceuticals, Inc. (SNOA) - REGDEX SEC Filings 01/13/2003
Sonoma Pharmaceuticals, Inc. (SNOA) - REGDEX SEC Filings 01/15/2002

Press Releases

StockPrice Release
Sonoma pharmaceuticals receives new fda 510(k) clearance for microcyn(r)-based wound care hydrogel 11/11/2024
Sonoma pharmaceuticals reports second fiscal quarter 2025 financial results 11/07/2024
Sonoma pharmaceuticals to exhibit at medica 2024 in dÜsseldorf 10/31/2024
Sonoma pharmaceuticals announces expanded partnership with global healthcare distributor for distribution of wound care products in canada 10/22/2024
Sonoma pharmaceuticals regains compliance with nasdaq minimum bid price rule 09/19/2024
Sonoma pharmaceuticals receives new fda 510(k) clearance with expanded indications for over-the-counter microcyn(r)-based solution 09/17/2024
Sonoma pharmaceuticals and emc pharma announce collaboration to co-market an expanded eye care product line 09/11/2024
Sonoma pharmaceuticals announces 1-for-20 reverse split of outstanding common stock 08/28/2024
Sonoma pharmaceuticals and microsafe group announce that nanocyn(r) disinfectant & sanitizer has been approved by the australian tga as effective against candida auris and c-diff 08/26/2024
Sonoma pharmaceuticals announces partnership with global healthcare distributor for distribution of wound care products in the united states 08/21/2024
Sonoma pharmaceuticals reports first fiscal quarter 2025 financial results 08/08/2024
Sonoma pharmaceuticals celebrates 20 years of selling wound care products in europe and announces new distributor in ukraine 07/09/2024
Sonoma pharmaceuticals reports fiscal year and fourth quarter 2024 financial results 06/17/2024
Sonoma pharmaceuticals announces microcynah for animal health now available through menards home improvement stores 05/09/2024
Sonoma pharmaceuticals announces expansion of negative-pressure wound therapy products for use in the united states 04/09/2024
Sonoma pharmaceuticals reports recent publication from australia highlighting potential for microdox in managing urinary tract infections 04/04/2024
Sonoma pharmaceuticals to present at trickle research and ld micro investor conferences 03/28/2024
Sonoma pharmaceuticals highlights safety advantages of its microcyn products in light of growing concerns of benzene in many other topicals 03/27/2024
Sonoma pharmaceuticals reports third fiscal quarter 2024 financial results 02/08/2024
Sonoma pharmaceuticals introduces lumacyn clarifying mist, an all natural, over-the-counter skincare product for daily use 01/23/2024
Novabay pharmaceuticals and sonoma pharmaceuticals agree to market avenova-branded products in the european union through sonoma's extensive distributor network 01/09/2024
Sonoma pharmaceuticals reports second fiscal quarter 2024 financial results 11/13/2023
Sonoma pharmaceuticals announces u.s. launch of next generation advanced solution for pulse lavage irrigation at the symposium on advanced wound care fall conference 11/03/2023
Sonoma pharmaceuticals, inc. announces pricing of $1.7 million public offering of common stock 10/26/2023
National eczema association awards seal of acceptance to sonoma pharmaceuticals for reliefacyn advanced 08/15/2023
Sonoma pharmaceuticals reports first fiscal quarter 2024 financial results 08/10/2023
Sonoma pharmaceuticals announces appointment of hye jin chung, m.d. to scientific advisory board 08/03/2023
Sonoma pharmaceuticals reports fiscal year and fourth quarter 2023 financial results 06/22/2023
Sonoma pharmaceuticals introduces next generation solution for pulse lavage irrigation in the european union 06/08/2023
Sonoma pharmaceuticals introduces podiacyn, an all natural, over-the-counter podiatry product for daily foot care 04/11/2023
Sonoma pharmaceuticals to exhibit at upcoming cphi north america conference in philadelphia 03/28/2023
Sonoma pharmaceuticals and microsafe group announce new epa claims and green seal certification for nanocyn(r) hospital-grade disinfectant 03/02/2023
Sonoma pharmaceuticals reports third quarter 2023 financial results 02/14/2023
Sonoma pharmaceuticals announces partnership with daewoong pharmaceutical for distribution of primocyn skin care in south korea 01/31/2023
Sonoma pharmaceuticals and emc pharma announce department of defense dapa registration for microcyn(r) rx products 01/25/2023
Sonoma pharmaceuticals launches two new products expanding its line of office dispense products exclusively for dermatologists and medical spas 01/04/2023
Sonoma pharmaceuticals reports second quarter 2023 financial results 11/14/2022
Sonoma pharmaceuticals to exhibit at upcoming cphi conference in frankfurt, germany 10/06/2022
Sonoma pharmaceuticals reports first quarter 2023 financial results 08/11/2022
Sonoma pharmaceuticals launches microcynvs(r) line of products exclusively for veterinarian use and announces partnership with dv medical supply 08/02/2022
Sonoma pharmaceuticals reports fiscal year and fourth quarter 2022 financial results 07/13/2022
Sonoma pharmaceuticals and microsafe group dmcc announce that u.s. epa has added nanocyn® hospital-grade disinfectant to list n for use against covid-19 06/01/2022
Sonoma pharmaceuticals and microsafe group dmcc announce epa approval for nanocyn® hospital-grade disinfectant in the u.s. 05/03/2022
Sonoma pharmaceuticals launches new urinary tract infection product through distributors in new zealand, australia and south africa 03/30/2022
Sonoma pharmaceuticals reports third quarter fy 2022 financial results 02/11/2022
Sonoma pharmaceuticals announces expansion of its partner network for oral and dental products in the u.s. and china 01/20/2022
Sonoma pharmaceuticals to present at h.c. wainwright bioconnect virtual conference january 10-13, 2022 01/05/2022
Sonoma pharmaceuticals and microsafe group announce that nanocyn® disinfectant & sanitizer has been approved by the australia tga with a 15 second sars-cov-2 (covid-19) kill time 10/15/2021
Sonoma pharmaceuticals announces expanded dental care line with a new product for professional care in the u.s. and a new product for professional and consumer care in switzerland 08/19/2021
Sonoma pharmaceuticals reports first quarter 2022 financial results 08/16/2021
Sonoma pharmaceuticals reports fiscal year and fourth quarter 2021 financial results 07/14/2021
Sonoma pharmaceuticals and emc pharma announce an exclusive partnership to expand commercial channels of the microcyn®-based rx dermatology and eye care products nationwide 03/31/2021
Sonoma pharmaceuticals alert: bragar eagel & squire, p.c. is investigating sonoma pharmaceuticals, inc. on behalf of sonoma stockholders and encourages investors to contact the firm 03/11/2021
Rosen, nationally regarded investor counsel, encourages sonoma pharmaceuticals, inc. investors with losses to inquire about securities class action investigation – snoa 03/09/2021
Sonoma pharmaceuticals to present at upcoming spring virtual investor conferences 03/04/2021
Rosen, respected investor counsel, encourages sonoma pharmaceuticals, inc. investors with losses to inquire about securities class action investigation - snoa 02/19/2021
Sonoma pharmaceuticals reports third quarter fy 2021 financial results 02/16/2021
Breaking alert: rosen, a longstanding and trusted firm, encourages sonoma pharmaceuticals, inc. investors with losses to inquire about securities class action investigation – snoa 02/15/2021
Ongoing investigation notice: the schall law firm announces it is investigating claims against sonoma pharmaceuticals, inc. and encourages investors with losses of $100,000 to contact the firm 02/08/2021
Sonoma pharmaceuticals and microderm technologies announce that dermodacyn® disinfecting solution is now available in hong kong and thailand 01/28/2021
Rosen, global investor counsel, continues to investigate securities claims against sonoma pharmaceuticals, inc. - snoa 01/18/2021
Sonoma pharmaceuticals to present at the h.c. wainwright bioconnect 2021 virtual conference 01/11/2021
Rosen, a leading investor firm, continues to investigate securities claims against sonoma pharmaceuticals, inc. – snoa 12/24/2020
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of sonoma pharmaceuticals, inc. - snoa 12/19/2020
Sonoma pharmaceuticals announces partnership with gabriel science, llc for dental markets 12/17/2020
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of sonoma pharmaceuticals, inc. - snoa 12/16/2020
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of sonoma pharmaceuticals, inc. - snoa 12/12/2020
Rosen, global investor counsel, continues its investigation of securities claims against sonoma pharmaceuticals, inc. - snoa 12/08/2020
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of sonoma pharmaceuticals, inc. - snoa 12/07/2020
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of sonoma pharmaceuticals, inc. – snoa 11/30/2020
Ongoing investigation alert: the schall law firm announces it is investigating claims against sonoma pharmaceuticals, inc. and encourages investors with losses of $100,000 to contact the firm 11/27/2020
Shareholder alert: pomerantz law firm investigates claims on behalf of investors of sonoma pharmaceuticals, inc. - snoa 11/25/2020
Sonoma pharmaceuticals, inc. investors: company investigated by the portnoy law firm 11/25/2020
Investigation reminder: the schall law firm announces it is investigating claims against sonoma pharmaceuticals, inc. and encourages investors with losses of $100,000 to contact the firm 11/25/2020
Rosen, a leading law firm, continues to investigate securities claims against sonoma pharmaceuticals, inc. - snoa 11/24/2020
Investigation alert: the schall law firm announces it is investigating claims against sonoma pharmaceuticals, inc. and encourages investors with losses of $100,000 to contact the firm 11/24/2020
Rosen, respected investor counsel, continues to investigate securities claims against sonoma pharmaceuticals, inc. - snoa 11/24/2020
Equity alert: rosen law firm announces investigation of securities claims against sonoma pharmaceuticals, inc. – snoa 11/24/2020
Sonoma pharmaceuticals reports second quarter fy 2021 financial results 11/20/2020
Sonoma pharmaceuticals, microsafe group announce health canada authorized nanocyn disinfectant, sanitizer to be sold in canada 09/17/2020
Sonoma pharma names jerry dvonch as new cfo 09/11/2020
Sonoma pharmaceuticals reports q1 eps of $0.54 08/14/2020
Sonoma pharmaceuticals reports qtrly loss per share of $0.77 07/10/2020
Sonoma pharmaceuticals entered into agreement with brill international 05/26/2020
Sonoma pharma says effective on april 14, board appointed grant edwards as new cfo 04/20/2020
Sonoma pharmaceuticals reports q3 shr loss $0.72 02/14/2020
Sonoma pharmaceuticals, inc. has completed a follow-on equity offering in the amount of $1.56302 million. 11/28/2019
Sonoma pharmaceuticals announces pricing of about $1.6 mln public offering of common stock 11/26/2019
Sonoma pharmaceuticals posts qtrly loss per share of $0.91 11/14/2019
Sonoma pharmaceuticals, inc. reports earnings results for the second quarter ended september 30, 2019 11/13/2019
Sonoma pharmaceuticals adjourns its annual general meeting 10/02/2019
Sonoma pharmaceuticals says amy trombly appointed as interim ceo 10/01/2019

More Headlines

News
Sonoma Pharmaceuticals Announces 1-for-20 Reverse Split of Outstanding Common Stock BOULDER, CO / ACCESSWIRE / August 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the timing for a 1-for-20 reverse split of its outstanding common stock which will be effected on August 29, 2024 at 5:00 pm EDT. Sonoma common stock will begin trading on The Nasdaq Capital Market on a 1-for-20 adjusted basis when the market opens on August 30, 2024. 08/28/2024
Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-Diff BOULDER, CO / ACCESSWIRE / August 26, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, and its partner, the MicroSafe Group DMCC, announce that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for Nanocyn® Disinfectant and Sanitizer, which is manufactured by Sonoma for its partner MicroSafe using Sonoma's patented Microcyn® technology. Nanocyn® was previously approved by the TGA and entered into The Australian Register of Therapeutic Goods with a 15 second kill time against SARS-CoV-2 (COVID 19), and a 30 second kill time against Norovirus (Gastro), Influenza A (H1N1), and bacteria, such as Staphylococcus aureus (MRSA), E. 08/26/2024
Sonoma Pharmaceuticals Announces Partnership with Global Healthcare Distributor for Distribution of Wound Care Products in the United States BOULDER, CO / ACCESSWIRE / August 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it has entered into a distribution agreement with a leading global healthcare distributor for the marketing and distribution of its wound care products in the United States. The agreement provides for the distribution of Sonoma's wound care products through an existing and extensive network of hospital systems and other healthcare channels in the United States. 08/21/2024
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2025 Financial Results European revenues increased 20% compared to same period last year Gross margin of 39% compared to 35% in same period last year Net loss improved 19% compared to same period last year BOULDER, CO / ACCESSWIRE / August 8, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal quarter ended June 30, 2024. "This year marks the twentieth anniversary of the introduction of Sonoma wound care products into Europe; it is remarkable how our business has expanded and diversified in that time," remarked Amy Trombly, CEO of Sonoma. 08/08/2024
Sonoma Pharmaceuticals (SNOA) Is Attractively Priced Despite Fast-paced Momentum Sonoma Pharmaceuticals (SNOA) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices. 07/15/2024
Sonoma Pharmaceuticals Celebrates 20 Years of Selling Wound Care Products in Europe and Announces New Distributor in Ukraine BOULDER, CO / ACCESSWIRE / July 9, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announces it is celebrating its 20th anniversary of selling wound care products in Europe. Sonoma is also proud to announce that it is expanding its distributor base in Europe by adding a new partnership with Smart Healthcare Company (SHC) s.r.o. 07/09/2024
Sonoma Pharmaceuticals (SNOA) Shows Fast-paced Momentum But Is Still a Bargain Stock If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen. 06/28/2024
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results Revenues increased 14% in Q4 2024 compared to Q4 2023 Gross profit margin improved 3% in FY 2024 compared to FY 2023 Net loss improved 18% in Q4 2024 compared to Q4 2023, and 6% in FY 2024 compared to FY 2023 BOULDER, CO / ACCESSWIRE / June 17, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for fiscal year 2024 and the fourth quarter ended March 31, 2024. "We are pleased to report continued product-related growth and reduced cash burn in both our fourth quarter and fiscal year 2024 results. 06/17/2024
Sonoma Pharmaceuticals Announces MicrocynAH for Animal Health Now Available Through Menards Home Improvement Stores BOULDER, CO / ACCESSWIRE / May 9, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the launch of its MicrocynAH® animal health care products in the Menards® chain of home improvement stores in the United States. Menards is a family-owned company started in 1958 and headquartered in Eau Claire, Wisconsin. 05/09/2024
Sonoma Pharmaceuticals Announces Expansion of Negative-Pressure Wound Therapy Products for Use in the United States BOULDER, CO / ACCESSWIRE / April 9, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced the expansion of its Microcyn® Negative-Pressure Wound Therapy (NPWT) Solution products in the United States. Microcyn Negative-Pressure Wound Therapy Solution, an innovation in advanced wound care, is now available in convenient sizes of 250mL, 450mL, and 990mL. 04/09/2024
Sonoma Pharmaceuticals Reports Recent Publication from Australia Highlighting Potential for Microdox in Managing Urinary Tract Infections BOULDER, CO / ACCESSWIRE / April 4, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and podiatry, reported a recent publication in the journal Neurourology and Urodynamics highlighting the potential for Microdox® in the management of urinary tract infections, or UTIs, in children with neurogenic or non‐neurogenic bladder dysfunction.[1] Microdox is a super-oxidized solution based on Sonoma's patented Microcyn technology intended to treat and prevent infections in the urinary tract and bladder. 04/04/2024
Sonoma Pharmaceuticals to Present at Trickle Research and LD Micro Investor Conferences BOULDER, CO / ACCESSWIRE / March 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced that it will be presenting at two upcoming investor conferences in Denver and New York. Trickle Research Spring 2024 Microcap Conference Sonoma will be presenting at the Trickle Research Spring 2024 Microcap Conference at Ball Arena in Denver, Colorado on April 2nd, 2024. 03/28/2024
Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals BOULDER, CO / ACCESSWIRE / March 27, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care and dermatological conditions, highlights the safety advantages of its Microcyn technology products in response to concerns related to benzoyl peroxide, a common ingredient in dermatology products. Recently, there have been concerns that popular dermatology products can form benzene, a known carcinogen. 03/27/2024
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2024 Financial Results Revenues increased 7% compared to quarter from prior year and 15% from prior quarter Improvement in gross margin for quarter of 19% compared to prior year Improvement in net loss for quarter of $1.0 million compared to prior year BOULDER, CO / ACCESSWIRE / February 8, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA),a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its third fiscal quarter and nine months ended December 31, 2023. "We are pleased to report increased revenues in the quarter ended December 31, 2023, both year over year and compared to the prior quarter," said Amy Trombly, CEO of Sonoma. 02/08/2024
Sonoma Pharmaceuticals Introduces Lumacyn Clarifying Mist, an All Natural, Over-the-Counter Skincare Product for Daily Use BOULDER, CO / ACCESSWIRE / January 23, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, today announced the launch of LumacynTM Clarifying Mist direct to consumers for over-the-counter use in the United States. Lumacyn Clarifying Mist is an anti-inflammatory and antibacterial spray that calms irritated skin using Sonoma's patented stabilized hypochlorous acid. 01/23/2024
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma's Extensive Distributor Network EMERYVILLE, CA and BOULDER, CO / ACCESSWIRE / January 9, 2024 / NovaBay Pharmaceuticals, Inc. (NYSE American:NBY) and Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced an agreement for the sale and marketing of Avenova®-branded products by Sonoma in the European Union. The new products will combine Sonoma's existing eye product Ocudox®, which has already received a Class IIB CE mark for sale in the European Union, with Avenova branding, and are expected to be marketed through Sonoma's established European distribution network. 01/09/2024
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2024 Financial Results Gross profit percentage of 36% for the quarter, up 1% from first fiscal quarter 2024 Total operating expenses decreased for the quarter and six months ended September 30, 2023 compared to same period prior year European revenues increased 3% for the quarter and 13% for the six months ended September 30, 2023, compared to the same periods prior year BOULDER, CO / ACCESSWIRE / November 13, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its second fiscal quarter ended September 30, 2023. "In the second quarter of our fiscal year 2024, we continued to reduce costs while maintaining our diligent efforts to expand sales and increase our presence in U.S. and international markets," said Amy Trombly, CEO of Sonoma. 11/13/2023
Sonoma Pharmaceuticals Announces U.S. Launch of Next Generation Advanced Solution for Pulse Lavage Irrigation at the Symposium on Advanced Wound Care Fall Conference BOULDER, CO / ACCESSWIRE / November 3, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced the U.S. launch of its intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical procedures. Sonoma previously launched its pulse lavage irrigation treatment solution in Europe and is introducing this product to the United States at the Symposium on Advanced Wound Care (SAWC) Fall Conference in Las Vegas. 11/03/2023
Sonoma Pharmaceuticals, Inc. Announces Pricing of $1.7 Million Public Offering of Common Stock BOULDER, CO / ACCESSWIRE / October 26, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, today announced the pricing of its public offering of 8,500,000 shares of common stock at a price of $0.20 per share. The gross proceeds of the offering to the Company, before deducting placement agent fees and commissions and estimated offering expenses, are expected to be approximately $1.7 million. 10/26/2023
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced BOULDER, CO / ACCESSWIRE / August 15, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced that Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel has received the National Eczema Association (NEA) Seal of Acceptance™. Reliefacyn Advanced is a direct-to-consumer product available for over-the-counter use. 08/15/2023
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial Results Revenue increased 6% in the first fiscal quarter compared to the same period last year, excluding a one-time event last year Margins remained consistent year over year in an inflationary period, excluding the one-time event Sonoma continued to manage cash tightly, using only $0.3 million of cash in its first fiscal quarter BOULDER, CO / ACCESSWIRE / August 10, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal quarter ended June 30, 2023. "We continued to grow our core business in the first fiscal quarter by adding new products, partners and territories while containing costs," said Amy Trombly, CEO of Sonoma. 08/10/2023
Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory Board BOULDER, CO / ACCESSWIRE / August 3, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced the appointment of Dr. Hye Jin Chung MD, MMSc, Assistant Professor of Dermatology at Harvard Medical School in Boston and practicing dermatologist at Beth Israel Deaconess Medical Center, to the company's Scientific Advisory Board. Sonoma's Scientific Advisory Board will be comprised of a small group of physicians with expertise in the areas of dermatology, skin care, wound care, eye, oral and nasal care, and animal health. 08/03/2023
Sonoma Pharmaceuticals Shares Soar 44% After Introducing New Product Sonoma Pharmaceuticals shares jumped 44% on Friday after the company unveiled a product that could replace IV bags for some surgeries. 06/09/2023
Markets End the Week in the Green in Anticipation the Fed Will Pause Rate Hikes Markets posted a winning day on Friday, June 9, 2023, to top off a winning week on optimism the Fed may pause its interest rate hike cycle next week. 06/09/2023
5 Penny Stocks To Watch With Big News This Week Penny stocks to watch with news. The post 5 Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 03/02/2023
7 Top Penny Stocks To Watch With Big News This Week Penny Stocks With News Light Up The Scanners This Week This week 01/31/2023
Why Investing in Penny Stocks Could Be Worth It Are penny stocks worth investing in? The post Why Investing in Penny Stocks Could Be Worth It appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 01/26/2023
Why Is Sonoma Pharmaceuticals (SNOA) Up 70% Today? Sonoma Pharmaceuticals (NASDAQ: SNOA ) stock is rocketing higher on Wednesday following positive news for its Microcyn Rx products. The big news here is Sonoma Pharmaceuticals getting a Distribution and Pricing Agreement (DAPA) from the Defense Logistics Agency ( DLA ). 01/25/2023
What Makes Penny Stocks an Attractive Investment? Are penny stocks on your watchlist right now? The post What Makes Penny Stocks an Attractive Investment? 11/03/2022
Why Is Sonoma Pharmaceuticals (SNOA) Stock Up 30% Today? Sonoma Pharmaceuticals (SNOA) stock is getting a boost on Tuesday after the company revealed positive disinfectant news from the EPA. The post Why Is Sonoma Pharmaceuticals (SNOA) Stock Up 30% Today? 05/03/2022
Best Penny Stocks to Buy Today? 3 to Watch on May 3rd What to know about buying penny stocks on May 3rd The post Best Penny Stocks to Buy Today? 3 to Watch on May 3rd appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 05/03/2022
Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today? Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today? 03/30/2022
Sonoma Pharma Launches New Urinary Tract Infection Product In New Zealand, Australia, South Africa Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) has launched Microdox, an urinary tract infection catheter and bladder rinse in New Zealand, Australia, and South Africa. Microdox is a super-oxidized solution based on Sonoma's patented Microcyn Technology intended to treat and prevent. 03/30/2022
Sonoma Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference January 10-13, 2022 WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced that it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference. The conference is being held on January 10-13, 2022 virtually. Amy Trombly, CEO and Jerry Dvon 01/05/2022
SNOA Stock: Why The Price Increased Substantially Today The stock price of Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) increased by over 20% pre-market today. This is why it happened. 10/15/2021
Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Been Approved by the Australia TGA with a 15 Second SARS-CoV-2 (COVID-19) Kill Time WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group, announce that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for Nanocyn® Disinfectant and Sanitizer, which is ma 10/15/2021
7 Popular Penny Stocks That You Shouldn't Touch With a 10-Foot Pole Penny stocks can be risky investments. These seven popular penny stocks seem like particularly bad bets no matter how you look at it. 10/05/2021
SNOA Stock: Why It Substantially Increased Today The stock price of Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) increased by over 65% pre-market today. This is why it happened. 09/28/2021
Why Are Sonoma Pharma Shares Rallying Today? Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) has announced the OTC consumer launch of Regenacyn Advanced Scar Gel and Ocucyn Eyelid & Eyelash Cleanser on Amazon.com and MucoClyns on Amazon sites in Europe. All three products are based on Sonoma's Microcyn technology and are immediately available for customer orders. 09/28/2021
Why Sonoma Pharmaceuticals Shares Are Trading Lower Today Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) is trading significantly lower Friday amid possible profit taking after the stock surged Thursday following the company's launch of two new dental products. Sonoma Pharmaceuticals launched OroGenix Oral Hygiene Rinse, which was developed with Gabriel Science and is the company's second dental product in the U.S. OroGenix Oral Hygiene Rinse uses Sonoma's patented Microcyn technology to cleanse teeth, gums, and mouth. 08/20/2021
What Did the Stock Market Do Today, Aug. 19? 3 Big Stories to Catch Up On. So what did the stock market do today? Investors are hunting for ways to play geeky themes such as metaverse stocks and lidar stocks. 08/19/2021
Why Sonoma Pharmaceuticals Shares Are Surging Higher Today Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) is surging higher Thursday after the company announced it launched two new dental products. Sonoma Pharmaceuticals launched OroGenix Oral Hygiene Rinse, which was developed with Gabriel Science and is the company's second dental product in the U.S. OroGenix Oral Hygiene Rinse uses Sonoma's patented Microcyn technology to cleanse teeth, gums, and mouth. 08/19/2021
SONN Stock: The Social Media Buzz Sending Sonnet Bio Rocketing Today Sonnet BioTherapeutics (SONN) stock is taking off on Thursday and investors can thank retail traders on social media for pumping it higher. The post SONN Stock: The Social Media Buzz Sending Sonnet Bio Rocketing Today appeared first on InvestorPlace. 08/19/2021
Sonoma Pharmaceuticals Shares Increase Over 95% Pre-Market: Why It Happened The shares of Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) increased over 95% pre-market. This is why it happened. 08/19/2021
Why Sonoma Pharmaceuticals Shares Are Getting Hammered Today Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) shares are trading lower by 18.6% at $6.25 after the company reported fourth-quarter EPS and sales results were down year-over-year. Sonoma Pharmaceuticals reported quarterly losses of $1.64 per share. 07/15/2021
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2021 Financial Results WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care and dermatological conditions today announced financial results for fiscal year 2021 and the fourth quarter ended March 31, 2021. “For the past 18 months we have been restructuring the Company to cut losses while positioning it for growth,” sa 07/14/2021
SNOA Stock Price Increased Over 20% Pre-Market: Why It Happened The stock price of Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) increased by over 20% pre-market. This is why it happened. 04/01/2021
Sonoma Pharmaceuticals and EMC Pharma Announce an Exclusive Partnership to Expand Commercial Channels of the Microcyn®-based Rx Dermatology and Eye Care Products Nationwide WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditions, today announced that it has entered into an agreement with EMC Pharma, LLC for the exclusive right to manage, market and distribute Sonoma's HOCl-based prescription dermatology and eye care products in the United Sta 03/31/2021
SONOMA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Is Investigating Sonoma Pharmaceuticals, Inc. on Behalf of Sonoma Stockholders and Encourages Investors to Contact the Firm NEW YORK--(BUSINESS WIRE)-- #FederalSecuritiesLaws--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) on behalf of Sonoma stockholders. Our investigation concerns whether Sonoma has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. Sonoma filed an 8-K with the SEC on November 17, 2020. The filing announced that the Comp 03/11/2021
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – SNOA NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Sonoma securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen 03/09/2021
Sonoma Pharmaceuticals to Present at Upcoming Spring Virtual Investor Conferences WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that CEO Amy Trombly and CFO Jerry Dvonch will present at the following upcoming virtual conferences. Event H.C. Wainwright Global Life Sciences Conference Date March 9-10, 2021 03/04/2021
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - SNOA New York, New York--(Newsfile Corp. - February 19, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Sonoma securities you may be entitled to compensation without payment of any out of pocket fees or costs through... 02/19/2021
Sonoma Pharmaceuticals Reports Third Quarter FY 2021 Financial Results WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions today announced financial results for its third fiscal quarter and nine months ended December 31, 2020. “We continue to effectively execute our business plan of increasing revenue while reducing our expense 02/16/2021
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm Los Angeles, California--(Newsfile Corp. - February 8, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. ("Sonoma" or "the Company") (NASDAQ: SNOA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sonoma filed an 8-K with the SEC on November 17, 2020.... 02/08/2021
Sonoma Pharmaceuticals and Microderm Technologies Announce that Dermodacyn® Disinfecting Solution is Now Available in Hong Kong and Thailand WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, disinfectant use and dermatological conditions, and Microderm Technologies Ltd. announce that Dermodacyn® disinfectant has received import clearance as a medical device for Thailand with the help from Microderm's partner VetSynova Co. 01/28/2021
ROSEN, GLOBAL INVESTOR COUNSEL, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA NEW YORK, Jan. 18, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially... 01/18/2021
Sonoma Pharmaceuticals to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that CEO Amy Trombly and CFO Jerry Dvonch will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021. The presentation is available for on 01/11/2021
ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. – SNOA NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public. On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma's “unaudited condensed consolidate 12/24/2020
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA NEW YORK, Dec. 19, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. 12/19/2020
Why Sonoma, Medicenna And Dare Bioscience Are Trading Higher Today Sonoma Pharmaceuticals (NASDAQ: SNOA) shares are trading higher on Friday after the company announced a partnership with Gabriel Science for dental markets. Sonoma is engaged in identifying, developing and commercializing differentiated therapies to patients living with chronic skin conditions. 12/18/2020
Sonoma Pharmaceuticals Announces Partnership with Gabriel Science, LLC For Dental Markets WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Gabriel Science enter into distribution agreement for the sale of HOCl-products into the dental markets. 12/17/2020
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA New York, New York--(Newsfile Corp. - December 16, 2020) - Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. ("Sonoma" or the "Company") (NASDAQ: SNOA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Sonoma and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining... 12/16/2020
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. 12/12/2020
Sonoma Pharmaceuticals News Alert: Why SNOA Stock Is Rocketing Higher Today Sonoma Pharmaceuticals (SNOA) is in the news Friday after announcing a deal with Crown Laboratories that has SNOA stock on the rise. The post Sonoma Pharmaceuticals News Alert: Why SNOA Stock Is Rocketing Higher Today appeared first on InvestorPlace. 12/11/2020
ROSEN, GLOBAL INVESTOR COUNSEL, Continues Its Investigation of Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA New York, New York--(Newsfile Corp. - December 8, 2020) - Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public.On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma's "unaudited... 12/08/2020
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. 12/07/2020
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sonoma Pharmaceuticals, Inc. – SNOA NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. (“Sonoma” or the “Company”) (NASDAQ: SNOA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. 11/30/2020
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm LOS ANGELES--(BUSINESS WIRE)---- $SNOA #SNOA--ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. 11/27/2020
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA NEW YORK, Nov. 25, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. ("Sonoma" or the "Company") (NASDAQ: SNOA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.... 11/25/2020
Sonoma Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses 11/25/2020
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sonoma Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm Los Angeles, California--(Newsfile Corp. - November 25, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sonoma Pharmaceuticals, Inc. ("Sonoma" or "the Company") (NASDAQ: SNOA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sonoma filed an 8-K with the SEC on November 17, 2020.... 11/25/2020
ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. - SNOA NEW YORK, Nov. 24, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially... 11/24/2020
Sonoma Pharmaceuticals Reports Second Quarter FY 2021 Financial Results WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions today announced financial results for its second fiscal quarter and six months ended September 30, 2020. It further announced that it had to restate its first quarter financial statements for the quarter en 11/20/2020

Unlock

SNOA Ratings Summary

SNOA Quant Ranking